Cognitive decline and dementia incidence have also been consistently associated with exposure to air pollution. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
67/100
Among 34 349 participants, 19 378 individuals who were free of stroke and dementia and had longitudinal BP, cognitive, and covariate data were included in the analysis. 2 key findings →
Design: longitudinal study Participants: 349 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
67/100
In this exploratory analysis of a US community-based cohort, several echocardiographic measures of lower LA function were significantly associated with an increased risk of subsequent dementia. 5 key findings →
Design: prospective cohort Participants: 4,096 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Head injury was associated with risk of dementia (hazard ratio [HR] = 1.44, 95% confidence interval [CI] = 1.3-1.57), with evidence of dose-response (1 head injury: HR = 1.25, 95% CI = 1.13-1.39, 2+ head injuries: HR = 2.14, 95% CI = 1.86-2.46). 3 key findings →
Design: cohort study Participants: 14,376 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
High concentrations of Abeta(1-40) but not Abeta(1-42) at baseline were associated with an increased risk of dementia. 5 key findings →
Design: cohort study Participants: 6,713 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
During mean follow-up of 2.1 (range 1.5-3.4) years, 146 incident cases of dementia were detected, of which 105 were Alzheimer's disease. 3 key findings →
Design: case-control study Participants: 6,870 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Of 6 952 440 vaccinated patients in the derivation cohort, 5 150 310 (74.1%) had two vaccine doses. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Studies were significantly heterogeneous in terms of country, outcomes assessed, and the timing of post-ED outcome assessments. 5 key findings →
Design: systematic review Participants: 7,940 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Elevated blood pressure during midlife, persistence of elevated blood pressure into late life, and, among nonhypertensives, a steep decline in blood pressure during mid- to late life were associated with an increased dementia risk in a community-based cohort. 5 key findings →
Participants: 1,440 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Previous conclusions of a lack of efficacy for cognitive training in MCI may have been influenced by not clearly defining the intervention. 1 key finding →
Design: systematic review Participants: 305 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A diagnosis of COPD is associated with an increased risk for MCI, particularly NA-MCI. 5 key findings →
Design: cross-sectional Participants: 1,425 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We re-assessed after longer follow-up time in the large population-based cohort of the Rotterdam Study whether smoking habits and pack-years of smoking are associated with the risk of dementia, Alzheimer disease (AD), and vascular dementia (VaD). 4 key findings →
Design: cohort study Participants: 6,868 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Individual conditions have been identified as risk factors for dementia; however, it is important to consider the role of multimorbidity, as conditions often co-occur. 4 key findings →
Design: cohort study Participants: 960 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Whether this results in an increased risk for dementia remains unclear. 4 key findings →
Design: prospective cohort Participants: 3,975 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The study consisted of 20 400 patients (9264 female [45.4%]; 1576 Black [7.7%], 3944 Latinx [19.3%], and 10 480 White [51.4%]), including 5100 patients with mTBI (median [IQR] age, 36.0 [25.0-51.0] years), 5100 patients with msTBI (median [IQR age, 35.0 [25.0-52.0] years), and 10 200 matched patients in the control group (median [IQR] age, 36.0 [25.0-51.0] years). 5 key findings →
Design: cohort study Participants: 400 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 172 patients were included (86 each in the sotatercept and placebo groups). 5 key findings →
Design: clinical trial Participants: 172 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among 13,875 individuals with nonmissing VRF and outcome data with up to 30 years of follow-up (25% Black, 54% female), 179 developed PD at a mean age of 73.4 years, 94 developed PDD at a mean age of 79.2 years, and 1,791 developed dementia without PD at a mean age of 79.7 years. 5 key findings →
Design: longitudinal study Participants: 13,875 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
67/100
Among 11 601 participants (mean [SD] age, 59.18 [9.41] years; 5569 male [48.0%]), 9145 (78.8%) were exposed to at least 1 ACE indicator, 4241 (36.6%) to at least 1 AAE indicator, and 3531 (30.4%) to both ACE and AAE markers. 5 key findings →
Design: cohort study Participants: 601 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
During 3697 person-years of follow-up (mean per person, 3.6 years), dementia developed in 30 of the 1015 participants. 5 key findings →
Participants: 1,015 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In older adults with multiple dementia risk factors, group-based CCT is a safe and effective intervention for enhancing overall cognition, memory and processing speed. 4 key findings →
Design: longitudinal study Participants: 80 Evidence: high
Full summary, score breakdown and related studies → Original source
Poor external validity can result in inadequate treatment decision information. 3 key findings →
Design: cohort study Evidence: high
Full summary, score breakdown and related studies → Original source
The results from our meta-analysis suggest that the incidence of falls of older adults living in nursing homes is high, and the risk factors for falls are various. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
67/100
Twenty-seven (27.3%) of the 99 women developed incident dementia. 5 key findings →
Design: longitudinal study Participants: 99 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Diabetes and prediabetes accelerate cognitive decline and might predict microvascular lesions among dementia-free older adults. 4 key findings →
Design: longitudinal study Participants: 2,746 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Incident AF was associated with an increased risk of dementia, independent of clinical stroke in an elderly population. 5 key findings →
Design: longitudinal study Participants: 435 Evidence: moderate
Full summary, score breakdown and related studies → Original source
From across this tag
9 of the 3,281 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Discontinuation of Statins in Veterans Admitted to Nursing Homes near the End of Life
- Physical Frailty, Cognitive Impairment, and the Risk of Neurocognitive Disorder in the Singapore Longitudinal Ageing Studies
- APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway
- Cardiovascular Risk Associated with Poorer Memory in Middle-Aged Adults from the Healthy Brain Project
- Global, regional, and national trends of dementia incidence and risk factors, 1990-2019: A Global Burden of Disease study
- Metabolic syndrome, mild cognitive impairment and Alzheimer's disease--the emerging role of systemic low-grade inflammation and adiposity
- Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
- Cognition and synaptic plasticity in diabetes mellitus
- Cross-sectional and longitudinal associations of circulating bile acids and dementia: a systematic review
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →